WuXi AppTec Passes FDA Inspection
News Apr 14, 2016
WuXi AppTec has announced that WuXi Lab Testing Division (LTD)’s late-and commercial-stage analytical and stability testing facilities in Shanghai successfully passed an FDA inspection for GMP compliance.
The inspector from FDA China office evaluated WuXi LTD’s quality system during a 4-day inspection, with focus on data integrity and compliance across its GMP analytical and stability testing facilities.
The inspection outcome confirmed WuXi’s adherence to FDA’s rigorous GMP guidance and its high quality of operation.
“FDA expects the highest quality and data integrity, and we are proud to receive a very positive feedback, ”said Dr. Ge Li, Chairman and CEO of WuXi AppTec, “ We will continue to uphold the highest quality standards and provide best-in-class R&D services for our customers worldwide.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018